Keros Therapeutics
KROS10.2202.51% ( +0.250 )
Keros Therapeutics (KROS)
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to...
- Open
- 9.920
- High
- 10.230
- Low
- 9.900
- Prev. Close
- 9.970
- Volume
- 136.32K
- Turnover
- 1.38M
- Avg Price
- 10.127
- Bid/Ask Ratio
- --
- Amplitude
- 3.31%
- 52wk High
- 22.550
- Volume Ratio
- 0.84
- Turnover Ratio
- 0.77%
Keros Therapeutics Analyst Rating
View MoreForecast & Rating
Jun 3, 2026Price forecast
$21.83113.63%
Forecast & RatingBuy
7analysts
- Strong buy42.86%
- Buy0.00%
- Hold57.14%
- Sell0.00%
- Strong sell0.00%
News
- PUBT · 15 hours ago
Keros Therapeutics to receive $20 million Takeda milestone payment for elritercept Phase 3 dosing
- PUBT · Jul 22 at 03:02 PM
Keros Therapeutics names Annita Tanini interim CFO as Keith Regnante resigns
- PUBT · Jul 17 at 03:10 PM
Keros Therapeutics Director Jean Jacques Bienaime buys USD 10,610 in common shares
- PUBT · Jul 6 at 03:27 PM
Keros Therapeutics director Anne Prener files initial beneficial ownership statement
- PUBT · Jun 25 at 03:01 PM
Keros Therapeutics appoints Anne Prener to board of directors
- PUBT · Jun 17 at 03:56 PM
Keros Therapeutics director Jean Jacques Bienaime buys $10,190 of common shares
